Le Lézard
Classified in: Health
Subject: PDT

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)


CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 21,045 shares of its common stock and an aggregate of 10,520 restricted stock units (RSUs) to 13 new employees under Blueprint Medicines' 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual's entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The options have an exercise price of $96.32 per share, which is equal to the closing price of Blueprint Medicines' common stock on April 30, 2021. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Blueprint Medicines' 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

SOURCE Blueprint Medicines Corporation


These press releases may also interest you

at 03:05
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces a proposed capital return of $100 million to its shareholders by way...

at 03:00
Fusion Pharmaceuticals Inc. (Nasdaq:...

at 03:00
Empowered, the esteemed educational program hosted by actress Meg Ryan, is proud to announce a collaborative effort with Memorial Hospital of Converse County (MHCC) in Wyoming for an upcoming episode focused on the challenges of rural healthcare,...

at 03:00
Today, TELUS Health released its TELUS Mental Health Index ("the Index") with reports that examine the mental health of employed people in Canada, the United States, the United Kingdom, Europe, Singapore, New Zealand and Australia. The Canadian...

at 02:05
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Participants will...

at 01:00
The last few years have shown us the continued importance of nurses and other health care professionals. Whether at a hospital, clinic, home, long-term care facility, or patient transport, we depend on knowledgeable, skilled, and compassionate...



News published on and distributed by: